Amneal Appoints Rochelle Fuhrmann New Chief Financial Officer

Dynamic finance executive's diverse international experience will support company's global expansion
January 09, 2014 07:00 AM Eastern Standard Time
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals LLC is pleased to announce that Rochelle Fuhrmann has joined the fast-growing generics manufacturer as Chief Financial Officer.
 
"Rochelle's strong leadership abilities, robust financial background, and broad industry experience bring tremendous value to Amneal as we expand our global reach in both generic and specialty pharmaceuticals"
 
Ms. Fuhrmann was most recently Senior Vice President, Finance at Warner Chilcott plc. She was responsible for the oversight and direction of the finance and accounting functions including corporate accounting, financial planning and analysis, tax, treasury, risk management, and internal audit as well as investor relations. She joined Warner Chilcott in June 2006 and held positions of increasing responsibility before her promotion to Senior Vice President in January 2011.
 
"Rochelle's strong leadership abilities, robust financial background, and broad industry experience bring tremendous value to Amneal as we expand our global reach in both generic and specialty pharmaceuticals," said Chirag Patel, co-CEO and Chairman of Amneal. "We welcome her strategic vision and proactive approach and are delighted that she has joined the Amneal family."
 
Prior to Warner Chilcott, Ms. Fuhrmann held various positions in finance, corporate accounting, and investor relations at AT&T Inc. She began her career at Coopers & Lybrand LLC (now PriceWaterhouseCoopers) in Boston. She holds a B.S. degree in accounting from the University of Rhode Island.
 
About Amneal Pharmaceuticals LLC
 
Amneal Pharmaceuticals LLC is a U.S.-based manufacturer of generic pharmaceuticals. Known as "Generic's New Generation®", Amneal prides itself on its unwavering commitment to quality, meaningful business relationships, and its innovative approach to maximizing value for all stakeholders. Extensive investment in R&D, an intelligently aggressive expansion strategy, and focus on vertical integration are key contributors to the company's impressive growth over the past several years. Amneal is headquartered in Bridgewater, New Jersey with manufacturing, R&D, packaging, sales and distribution facilities throughout the U.S., as well as abroad. For more information, visit www.amneal.com.
 
Contacts
Amneal Pharmaceuticals LLC
Jim Luce, Executive Vice President, Sales & Marketing
M: 949-500-5756
www.amneal.com
or
Cheryl Lechok Communications, LLC
Cheryl Lechok, President
Dir: 203-961-9280
M: 203-613-1506

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.